Autoimmune myopathies: Autoantibodies, phenotypes and pathogenesis

Andrew L. Mammen

Research output: Contribution to journalArticle

Abstract

The different autoimmune myopathiesg-for example, dermatomyositis, polymyositis, and immune-mediated necrotizing myopathies (IMNM)g-have unique muscle biopsy findings, but they also share specific clinical features, such as proximal muscle weakness and elevated serum levels of muscle enzymes. Furthermore, around 60% of patients with autoimmune myopathy have been shown to have a myositis-specific autoantibody, each of which is associated with a distinct clinical phenotype. The typical clinical presentations of the autoimmune myopathies are reviewed here, and the different myositis-specific autoantibodies, including the anti-synthetase antibodies, dermatomyositis- associated antibodies, and IMNM-associated antibodies, are discussed in detail. This Review also focuses on a newly recognized form of IMNM that is associated with statin use and the production of autoantibodies that recognize 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the pharmacological target of statins. The contribution of interferon signaling to the development of dermatomyositis and the potential link between malignancies and the initiation of autoimmune myopathies are also assessed.

Original languageEnglish (US)
Pages (from-to)343-354
Number of pages12
JournalNature Reviews Neurology
Volume7
Issue number6
DOIs
Publication statusPublished - May 2011

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this